Search Clinical Trials
583,298 trials
ID
Status
Phase
Title
Sponsor
NCT07571369
Stress Modulation and Dynamic BalanceKafrelsheikh UniversityNot Yet RecruitingNot Applicable
NCT07571369Not Yet Recruiting
Not Applicable
Stress Modulation and Dynamic BalanceKafrelsheikh University
NCT07569068
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaRuijin HospitalRecruitingPhase 2
NCT07569068Recruiting
Phase 2
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Posit...Ruijin Hospital
NCT07569926
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrenceBlue Earth DiagnosticsNot Yet RecruitingPhase 4
NCT07569926Not Yet Recruiting
Phase 4
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Managemen...Blue Earth Diagnostics
NCT07569380
Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only TreatmentRegion VästerbottenNot Yet Recruiting
NCT07569380Not Yet Recruiting
—
Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only TreatmentRegion Västerbotten
NCT07569055
Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell TransplantationFirst Affiliated Hospital of Guangxi Medical UniversityRecruiting
NCT07569055Recruiting
—
Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoie...First Affiliated Hospital...
NCT07571824
A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy SubjectsCorium Innovations, Inc.RecruitingPhase 1
NCT07571824Recruiting
Phase 1
A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy...Corium Innovations, Inc.
NCT07569042
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed GlioblastomaNovelwise Pharmaceutical CorporationRecruitingPhase 1
NCT07569042Recruiting
Phase 1
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Ne...Novelwise Pharmaceutical...
NCT07569367
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia SpectrumBioSensicsNot Yet Recruiting
NCT07569367Not Yet Recruiting
—
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotem...BioSensics
NCT07571395
Median Nerve Electromyography to Monitor Intraoperative Neuromuscular FunctionPongrácz AdriennNot Yet Recruiting
NCT07571395Not Yet Recruiting
—
Median Nerve Electromyography to Monitor Intraoperative Neuromuscular FunctionPongrácz Adrienn
NCT07571902
Revised-Paravertebral Nerve Blocks for Enhanced Recovery After Stoma ClosureSixth Affiliated Hospital, Sun Yat-sen UniversityNot Yet RecruitingNot Applicable
NCT07571902Not Yet Recruiting
Not Applicable
Revised-Paravertebral Nerve Blocks for Enhanced Recovery After Stoma ClosureSixth Affiliated Hospital...
NCT07569458
Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)Aalborg University HospitalRecruitingNot Applicable
NCT07569458Recruiting
Not Applicable
Online Personalized Psychological Intervention for Patients With Heart Disease a...Aalborg University Hospit...
NCT07571343
Fueling Labor: Protein Supplementation for Intrapartum Glucose ControlMedical College of WisconsinNot Yet RecruitingNot Applicable
NCT07571343Not Yet Recruiting
Not Applicable
Fueling Labor: Protein Supplementation for Intrapartum Glucose ControlMedical College of Wiscon...
NCT07570849
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaShanghai Zhongshan HospitalRecruitingPhase 2
NCT07570849Recruiting
Phase 2
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment f...Shanghai Zhongshan Hospit...
NCT07570082
Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsCrinetics Pharmaceuticals Inc.RecruitingPhase 1
NCT07570082Recruiting
Phase 1
Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsCrinetics Pharmaceuticals...
NCT07570368
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast CancerUniversitas AirlanggaNot Yet RecruitingNot Applicable
NCT07570368Not Yet Recruiting
Not Applicable
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to E...Universitas Airlangga
NCT07569081
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeGlaxoSmithKlineNot Yet RecruitingPhase 2
NCT07569081Not Yet Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With V...GlaxoSmithKline
NCT07571005
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNovo Nordisk A/SNot Yet RecruitingPhase 3
NCT07571005Not Yet Recruiting
Phase 3
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps...Novo Nordisk A/S
NCT07569783
tDCS for Reducing the Incidence of OEI After Cesarean SectionAffiliated Hospital of Nantong UniversityNot Yet RecruitingNot Applicable
NCT07569783Not Yet Recruiting
Not Applicable
tDCS for Reducing the Incidence of OEI After Cesarean SectionAffiliated Hospital of Na...
NCT07569692
(PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography)-2CardioVascular Research Foundation, KoreaNot Yet RecruitingNot Applicable
NCT07569692Not Yet Recruiting
Not Applicable
(PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulne...CardioVascular Research F...
Result Breakdown
Not yet recruiting12 (60%)
Recruiting7 (35%)
Enrolling by invitation1 (5%)
not_applicable8 (40%)
Not Specified4 (20%)
Phase 23 (15%)
Phase 13 (15%)
Phase 41 (5%)
Phase 31 (5%)